Jeffrey E. Gershenwald

59.4k total citations · 11 hit papers
283 papers, 25.5k citations indexed

About

Jeffrey E. Gershenwald is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Jeffrey E. Gershenwald has authored 283 papers receiving a total of 25.5k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Oncology, 97 papers in Molecular Biology and 53 papers in Epidemiology. Recurrent topics in Jeffrey E. Gershenwald's work include Cutaneous Melanoma Detection and Management (177 papers), Melanoma and MAPK Pathways (69 papers) and Nonmelanoma Skin Cancer Studies (50 papers). Jeffrey E. Gershenwald is often cited by papers focused on Cutaneous Melanoma Detection and Management (177 papers), Melanoma and MAPK Pathways (69 papers) and Nonmelanoma Skin Cancer Studies (50 papers). Jeffrey E. Gershenwald collaborates with scholars based in United States, Australia and Italy. Jeffrey E. Gershenwald's co-authors include Merrick I. Ross, Charles M. Balch, John F. Thompson, John M. Kirkwood, Kelly M. McMasters, Daniel G. Coit, Jeffrey E. Lee, Michael B. Atkins, Paul F. Mansfield and Arthur J. Sober and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jeffrey E. Gershenwald

277 papers receiving 24.9k citations

Hit Papers

Final Version of 2009 AJCC Melanoma Staging and Classi... 1999 2026 2008 2017 2009 2001 2001 2017 1999 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of 2009 AJCC Melanoma Staging and Classification
    2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  2. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
    2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
  3. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
    2001 1.8k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  4. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 1.4k citations Jeffrey E. Gershenwald, Richard A. Scolyer et al. profile →
  5. Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients
    1999 865 citations Jeffrey E. Gershenwald, Jeffrey E. Lee et al. Journal of Clinical Oncology profile →
  6. NRAS mutation status is an independent prognostic factor in metastatic melanoma
    2011 528 citations Roland L. Bassett, Jonathan L. Curry et al. profile →
  7. Melanoma
    2015 441 citations Dirk Schadendorf, Jeffrey E. Gershenwald et al. profile →
  8. Guidelines of care for the management of primary cutaneous melanoma
    2018 393 citations Jeffrey E. Gershenwald, Timothy M. Johnson et al. profile →
  9. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system
    2010 383 citations Timothy M. Johnson, Merrick I. Ross et al. profile →
  10. Cutaneous melanoma
    2023 350 citations Jeffrey E. Gershenwald, Richard A. Scolyer et al. profile →
  11. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
    2018 336 citations Emily Z. Keung, Jeffrey E. Gershenwald profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey E. Gershenwald United States 72 19.6k 9.8k 5.7k 5.0k 3.1k 283 25.5k
Kelly M. McMasters United States 69 15.0k 0.8× 6.3k 0.6× 5.1k 0.9× 3.4k 0.7× 2.1k 0.7× 434 23.5k
Claus Garbe Germany 93 21.3k 1.1× 15.0k 1.5× 6.3k 1.1× 7.0k 1.4× 6.3k 2.1× 750 34.4k
Klaus J. Busam United States 80 16.6k 0.8× 9.3k 0.9× 3.2k 0.6× 4.2k 0.8× 3.3k 1.1× 426 24.8k
Alexander M.M. Eggermont Netherlands 72 18.5k 0.9× 9.4k 1.0× 3.5k 0.6× 6.7k 1.3× 1.8k 0.6× 389 25.8k
Richard A. Scolyer Australia 84 21.3k 1.1× 13.3k 1.4× 4.1k 0.7× 6.6k 1.3× 2.7k 0.9× 707 30.6k
Martín C. Mihm United States 94 20.4k 1.0× 9.2k 0.9× 5.4k 0.9× 8.2k 1.6× 7.7k 2.5× 456 34.5k
Vernon K. Sondak United States 71 16.6k 0.8× 8.3k 0.8× 3.4k 0.6× 5.7k 1.1× 1.9k 0.6× 432 22.6k
Merrick I. Ross United States 90 24.6k 1.3× 8.2k 0.8× 7.3k 1.3× 5.4k 1.1× 4.2k 1.4× 425 34.7k
Douglas S. Reintgen United States 69 14.7k 0.8× 4.4k 0.5× 5.4k 0.9× 2.8k 0.6× 2.8k 0.9× 252 20.4k
Donald L. Morton United States 86 22.7k 1.2× 10.4k 1.1× 6.8k 1.2× 8.8k 1.8× 3.0k 1.0× 448 33.4k

Countries citing papers authored by Jeffrey E. Gershenwald

Since Specialization
Citations

This map shows the geographic impact of Jeffrey E. Gershenwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey E. Gershenwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey E. Gershenwald more than expected).

Fields of papers citing papers by Jeffrey E. Gershenwald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey E. Gershenwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey E. Gershenwald. The network helps show where Jeffrey E. Gershenwald may publish in the future.

Co-authorship network of co-authors of Jeffrey E. Gershenwald

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey E. Gershenwald. A scholar is included among the top collaborators of Jeffrey E. Gershenwald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey E. Gershenwald. Jeffrey E. Gershenwald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burton, Elizabeth M., Ashley Cimino‐Mathews, Tricia R. Cottrell, et al.. (2024). 1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort. Annals of Oncology. 35. S1127–S1128.
2.
Asare, Elliot A., Sarah B. Fisher, Yi‐Ju Chiang, et al.. (2023). Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. Journal of Surgical Oncology. 128(2). 313–321. 5 indexed citations
3.
Ascierto, Paolo A., Michael B. Atkins, Alexander M.M. Eggermont, et al.. (2021). The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine. 19(1). 142–142. 1 indexed citations
4.
Lucci, Anthony, Carolyn Hall, Sapna P. Patel, et al.. (2020). Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research. 26(8). 1886–1895. 52 indexed citations
5.
Capparelli, Claudia, Timothy J. Purwin, Inna Chervoneva, et al.. (2018). ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research. 78(19). 5680–5693. 13 indexed citations
6.
Bezrookove, Vladimir, Mehdi Nosrati, James R. Miller, et al.. (2018). Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical Cancer Research. 24(17). 4119–4125. 10 indexed citations
7.
Nagarajan, Priyadharsini, Jonathan L. Curry, Jing Ning, et al.. (2016). Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research. 23(8). 2093–2104. 37 indexed citations
8.
Bucheit, Amanda D., Guo Chen, Alan Siroy, et al.. (2014). Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAF V600 Mutations. Clinical Cancer Research. 20(21). 5527–5536. 109 indexed citations
9.
Slingluff, Craig L., Gina R. Petroni, David L. Brautigan, et al.. (2013). Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research. 19(13). 3611–3620. 28 indexed citations
10.
Thompson, John F., Seng-Jaw Soong, Charles M. Balch, et al.. (2011). Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. Journal of Clinical Oncology. 29(16). 2199–2205. 250 indexed citations
11.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2010). Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. Journal of Clinical Oncology. 28(14). 2452–2459. 287 indexed citations
12.
Ellerhorst, Julie A., Victoria R. Greene, Sühendan Ekmekçioglu, et al.. (2010). Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma. Clinical Cancer Research. 17(2). 229–235. 187 indexed citations
13.
Wei, Xiaomu, Todd D. Prickett, Cristina G. Viloria, et al.. (2010). Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma. Molecular Cancer Research. 8(11). 1513–1525. 41 indexed citations
14.
Davies, Michael A., Katherine Stemke‐Hale, E. Lin, et al.. (2009). Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research. 15(24). 7538–7546. 159 indexed citations
15.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2009). Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 27(36). 6199–6206. 3342 indexed citations breakdown →
16.
Staquicini, Fernanda I., Anita Tandle, Steven K. Libutti, et al.. (2008). A Subset of Host B Lymphocytes Controls Melanoma Metastasis through a Melanoma Cell Adhesion Molecule/MUC18-Dependent Interaction: Evidence from Mice and Humans. Cancer Research. 68(20). 8419–8428. 59 indexed citations
17.
Beadle, Beth M., B. Ashleigh Guadagnolo, Matthew T. Ballo, et al.. (2008). Radiation Treatment Field Delineation for Axillary Metastases from Malignant Melanoma. International Journal of Radiation Oncology*Biology*Physics. 72(1). S105–S106. 1 indexed citations
18.
Cormier, Janice N., Yan Xing, Meichun Ding, et al.. (2007). Cost Effectiveness of Adjuvant Interferon in Node-Positive Melanoma. Journal of Clinical Oncology. 25(17). 2442–2448. 20 indexed citations
19.
Xie, Tongxin, Kenneth Aldape, Shin-Hyuk Kang, et al.. (2006). Activation of Stat3 in Human Melanoma Promotes Brain Metastasis. Cancer Research. 66(6). 3188–3196. 312 indexed citations
20.
Ballo, Matthew T., Gunar K. Zagars, Erich M. Sturgis, et al.. (2004). Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease. International Journal of Radiation Oncology*Biology*Physics. 60. S256–S257. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelly M. McMasters Breakdown of academic impact, for papers by Claus Garbe Breakdown of academic impact, for papers by Klaus J. Busam Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Martín C. Mihm Breakdown of academic impact, for papers by Vernon K. Sondak Breakdown of academic impact, for papers by Merrick I. Ross Breakdown of academic impact, for papers by Douglas S. Reintgen Breakdown of academic impact, for papers by Donald L. Morton
Rankless by CCL
2026